RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

NCT04597125 · clinicaltrials.gov ↗
PHASE4
Phase
ACTIVE_NOT_RECRUITING
Status
654
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bayer